We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Hmn2.0
Humanin Research
Mostly mechanism / observational
10 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Humanin studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality studies published 2001–2026 with a typical study size of 602 participants.
Based on 10 studies · 602 total participants
Confidence
Low confidence
By outcome
Mitochondrial & aging biologyA mitochondrial-derived peptide with anti-apoptotic cytoprotection studied as a geroprotective/healthspan signal; no human efficacy trials and unknown human safety. · Not established (no human data)
Mostly mechanism / observational9 studies
Neuroprotection (preclinical)Neuroprotective in preclinical models (originally identified in an Alzheimer's context); unproven in humans. · Not established (no human data)
Mostly mechanism / observational5 studies
Metabolic effects (preclinical)Insulin-sensitizing/metabolic effects in preclinical models; no human data. · Not established (no human data)
Mostly mechanism / observational4 studies
Active research area
5 studies in the last 5 years
200120132026
1Review2026
In plain English: This review summarizes current insights into MDP biology and highlights its emerging therapeutic potential in chronic liver disease.
Thoudam T, Zeng G, Gao H, Jiang Y, Huda N, Yang Z, Ma J, Liangpunsakul S. · Hepatology communications (2026)
MOTS-c activates AMPK, regulates nuclear gene expression, suppresses fibrotic and inflammatory signaling, and restores mitochondrial function in MASLD and fibrosis models.
SHLPs, particularly SHLP2, enhance mitochondrial function and insulin sensitivity, supporting glucose homeostasis and mitigating oxidative stress.
Collectively, MDPs establish a novel paradigm in mitochondrial signaling, extending mtDNA function beyond energy production.
Zhou Q, Yin S, Lei X, Tian Y, Lin D, Wang L, Chen Q. · Diabetology & metabolic syndrome (2024)
The statistical analysis was summarized using the standardized mean difference (SMD) and 95% confidence interval (95% CIs).
Overall analysis results showed plasma MOTS-c concentration in diabetes and obesity patients was significantly reduced (SMD = - 0.37; 95% CI- 0.53 to - 0.20; P < 0.05).
After subgroup analysis, the present analysis has yielded opposite results for MOTS-c changes in obesity (SMD = 0.51; 95% CI 0.21 to 0.81; P < 0.05) and type 2 diabetes mellitus (T2DM) (SMD = - 0.89; 95% CI - 1.12 to - 0.65; P < 0.05) individuals.
In plain English: The current review will focus on the MDP regulation of T2D, T1D, and gestational diabetes along with an emphasis on the evolutionary pressures for conservation of the amino acid sequences of MDPs.
Special genetic codes are used in mtDNA as compared to nuclear DNA: (i) ATA and ATT are used as start codons in addition to the standard start codon ATG; (ii) AGA and AGG are used as stop codons instead of coding for arginine; (iii) the standard stop codon UGA is used to code for tryptophan.
While HN, SHLP6, and MOTS-c are encoded by the H (heavy owing to high guanine + thymine base composition)-strand of the mtDNA, SHLP1-5 are encoded by the L (light owing to less guanine + thymine base composition)-strand.
MDPs attenuate disease pathology including Type 1 diabetes (T1D), Type 2 diabetes (T2D), gestational diabetes, Alzheimer's disease (AD), cardiovascular diseases, prostate cancer, and macular degeneration.
In plain English: This review may provide valuable information with MDPs for CVD diagnosis and treatment.
Li Y, Li Z, Ren Y, Lei Y, Yang S, Shi Y, Peng H, Yang W, Guo T, Yu Y, Xiong Y. · Journal of advanced research (2024)
In this review, we delve into the biogenesis, various types, and diverse functions of MDPs.
We aim to shed light on the pivotal roles and the underlying mechanisms through which MDPs contribute to the onset and advancement of CVDs connecting cell apoptosis, inflammation, and oxidative stress.
We also provide insights into the current advancements in clinical research related to the utilization of MDPs in the treatment of CVDs.
In plain English: Collectively, the sORF-encoded microproteome represents an epigenetically integrated and functionally significant regulatory layer of the human proteome with major implications for fundamental biology and precision medicine.
Mustafa AM, Ali RM, Omar SS, Karim SO, Mohammed SH, Hamasalih HM, Ezzat SL, Ahmad AD, Mohammed KK, Kakamad FH. · Epigenomics (2026)
Their expression is tightly controlled by epigenetic mechanisms, including DNA methylation, Polycomb-mediated H3K27 trimethylation, and bivalent histone modifications, as well as epitranscriptomic regulation through N6-methyladenosine-mediated translation.
Key microproteins such as Humanin, MOTS-c, Myoregulin, DWORF, HOXB-AS3-p, Mitoregulin, and CASIMO1 illustrate the diverse roles of sORF-derived peptides in cardiometabolic disease, neurodegeneration, and cancer.
The review also highlights emerging therapeutic strategies, including epigenome editing, peptide replacement, and immunopeptidome-based neoantigen targeting.